Heart failure (HF) remains a large medical problem, and prevention of decompensation and HF-related hospitalizations is important, not only for the patient, but also from an economic point of view. Close monitoring is crucial, and can be done through a whole spectrum of modalities. This ranges from a (nurse-based) disease management program, to structured telephone support, to remote or telemonitoring with or without the use of an implantable device(1-3). (SELECT FULL TEXT TO CONTINUE).
[Show abstract][Hide abstract] ABSTRACT: Heart failure patients with implantable defibrillators place a significant burden on health care systems. Remote monitoring allows assessment of device function and heart failure parameters, and may represent a safe, effective, and cost-saving method compared to conventional in-office follow-up.
We hypothesized that remote device monitoring represents a cost-effective approach. This paper summarizes the economic evaluation of the Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study, a multicenter clinical trial aimed at measuring the benefits of remote monitoring for heart failure patients with implantable defibrillators.
Two hundred patients implanted with a wireless transmission-enabled implantable defibrillator were randomized to receive either remote monitoring or the conventional method of in-person evaluations. Patients were followed for 16 months with a protocol of scheduled in-office and remote follow-ups. The economic evaluation of the intervention was conducted from the perspectives of the health care system and the patient. A cost-utility analysis was performed to measure whether the intervention was cost-effective in terms of cost per quality-adjusted life year (QALY) gained.
Overall, remote monitoring did not show significant annual cost savings for the health care system (€1962.78 versus €2130.01; P=.80). There was a significant reduction of the annual cost for the patients in the remote arm in comparison to the standard arm (€291.36 versus €381.34; P=.01). Cost-utility analysis was performed for 180 patients for whom QALYs were available. The patients in the remote arm gained 0.065 QALYs more than those in the standard arm over 16 months, with a cost savings of €888.10 per patient. Results from the cost-utility analysis of the EVOLVO study show that remote monitoring is a cost-effective and dominant solution.
Remote management of heart failure patients with implantable defibrillators appears to be cost-effective compared to the conventional method of in-person evaluations.
ClinicalTrials.gov NCT00873899; http://clinicaltrials.gov/show/NCT00873899 (Archived by WebCite at http://www.webcitation.org/6H0BOA29f).
Journal of Medical Internet Research 05/2013; 15(5):e106. DOI:10.2196/jmir.2587 · 3.43 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Heart failure with normal left ventricular (LV) ejection fraction (HF-NEF), sometimes named diastolic heart failure, is a common condition, most frequent in the elderly and is associated with arterial hypertension and LV hypertrophy. Prognosis is almost as severe as for heart failure with reduced EF, in part reflecting comorbidities. Because the heart failure diagnosis is based on relatively nonspecific symptoms and signs, it is important to apply objective measures of diastolic function when evaluating patients with potential HF-NEF. In the absence of invasive data, this is done by echocardiography to demonstrate signs of impaired relaxation, increased diastolic stiffness, or elevated LV filling pressure. The echocardiographic measures include transmitral, pulmonary venous, and intraventricular flow velocities and estimation of systolic pulmonary artery pressure from tricuspid regurgitation velocity. In addition, LV lengthening velocity by tissue Doppler should be measured. It is important to search for consistency between measures since no single variable provides sufficient diagnostic information. Treatment of HF-NEF is symptomatic, with similar drugs as in heart failure with reduced EF.
Translational Approach to Heart Failure, Edited by Bartunek J, Vanderheyden M, 01/2013: chapter Heart Failure with Normal Left Ventricular Ejection Fraction: Basic Principles and Clinical Diagnosis: pages 25-63; Springer Science., ISBN: 978-1-4614-7344-2
[Show abstract][Hide abstract] ABSTRACT: Remote monitoring (RM) in patients with advanced heart failure and cardiac resynchronization therapy defibrillators (CRT-D) may reduce delays in clinical decisions by transmitting automatic alerts. However, this strategy has never been tested specifically in this patient population, with alerts for lung fluid overload, and in a European setting.
The main objective of Phase 1 (presented here) is to evaluate if RM strategy is able to reduce time from device-detected events to clinical decisions.
In this multicenter randomized controlled trial, patients with moderate to severe heart failure implanted with CRT-D devices were randomized to a Remote group (with remote follow-up and wireless automatic alerts) or to a Control group (with standard follow-up without alerts). The primary endpoint of Phase 1 was the delay between an alert event and clinical decisions related to the event in the first 154 enrolled patients followed for 1 year.
The median delay from device-detected events to clinical decisions was considerably shorter in the Remote group compared to the Control group: 2 (25(th)-75(th) percentile, 1-4) days vs 29 (25(th)-75(th) percentile, 3-51) days respectively, P=.004. In-hospital visits were reduced in the Remote group (2.0 visits/patient/year vs 3.2 visits/patient/year in the Control group, 37.5% relative reduction, P<.001). Automatic alerts were successfully transmitted in 93% of events occurring outside the hospital in the Remote group. The annual rate of all-cause hospitalizations per patient did not differ between the two groups (P=.65).
RM in CRT-D patients with advanced heart failure allows physicians to promptly react to clinically relevant automatic alerts and significantly reduces the burden of in-hospital visits.
Clinicaltrials.gov NCT00885677; http://clinicaltrials.gov/show/NCT00885677 (Archived by WebCite at http://www.webcitation.org/6IkcCJ7NF).
Journal of Medical Internet Research 08/2013; 15(8):e167. DOI:10.2196/jmir.2608 · 3.43 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.